Translocator protein (TSPO) positron emission tomography imaging and expression in patients with brain metastases
Authors:
- Paolo Zanotti-FregonaraPZPaolo Zanotti-Fregonara
- Monika VishnoiMVMonika Vishnoi
- John D. PattersonJPJohn D. Patterson
- Aboud TahanisATAboud Tahanis
- David R. BeersDBDavid R. Beers
- Oluwaseun B. OgunbonaOOOluwaseun B. Ogunbona
- Belen PascualBPBelen Pascual
- Joseph C. MasdeuJMJoseph C. Masdeu
- Steve H. FungSFSteve H. Fung
- Nafiseh GhazanfariNGNafiseh Ghazanfari
- Kanayo IkenemeKIKanayo Ikeneme
- 30 July 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (1) , 505-517
Abstract
Purpose 18 kDa translocator protein (TSPO) is a biomarker for inflammatory conditions. However, full kinetic positron emission tomography (PET) modeling has rarely been used to quantify brain tumors, and it has never been used in brain metastases (BMs). This proof-of-principle study quantified TSPO expression using full kinetic modeling in patients with BMs from various types of peripheral primary tumors. Methods Nine adult patients with BMs and 12 healthy volunteers (HVs) took part in the study. The total distribution volume (VT) of 11C-ER176 was calculated with a two-tissue compartment model (2TCM) and metabolite-corrected arterial input function in the BMs and in the rest of the brain. Immunohistochemistry (IHC) and single-cell RNAseq database were used to quantify TSPO expression in vitro. The VT values of the hemisphere contralateral to the BMs were compared to the cortical values of HVs. Results 11C-ER176 uptake was increased in BMs compared with the rest of the brain of each participant. The BM time-activity curves were well-fitted by the 2TCM, and the resulting VT (range 3.2–13 mL/cm3) was identified with precision (standard error generally < 5%). The rate constant mostly affected by the integrity of the blood–brain barrier (BBB) (K1) was similar between the BMs and the contralateral hemisphere. TSPO expression was detected by IHC in tumor regions and variably in microglia/macrophages, a finding largely corroborated by single-cell RNAseq database. The average VT of the rest of the brain in BM patients was significantly lower than in HVs, which may have been due to immunosuppressive therapy. Conclusion In this pilot study, full kinetic modeling quantified TSPO expression in BMs with good fit and precision. The kinetic modeling outcome parameters and the TSPO expression levels in vitro suggest that 11C-ER176 binding was largely specific and not significantly affected by disruption of the BBB.Keywords
Funding Information
- Young Texans Against Cancer
This publication has 38 references indexed in Scilit:
- From pre-clinical to translational brain metastasis research: current challenges and emerging opportunitiesClinical & Experimental Metastasis, 2024
- TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomasEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibitionJournal of Neuro-Oncology, 2022
- Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?European Journal of Nuclear Medicine and Molecular Imaging, 2022
- Preclinical evaluation of (S)-[18F]GE387, a novel 18-kDa translocator protein (TSPO) PET radioligand with low binding sensitivity to human polymorphism rs6971European Journal of Nuclear Medicine and Molecular Imaging, 2021
- A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain MetastasisThe Oncologist, 2020
- Anatomy of 18F-GE180, a failed radioligand for the TSPO proteinEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- The validity of 18F-GE180 as a TSPO imaging agentEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobeHuman Brain Mapping, 2003
- Evaluation of Ultrafiltration for the Free‐Fraction Determination of Single Photon Emission Computed Tomography (SPECT) Radiotracers: β‐CIT, IBF, and IomazenilJournal of Pharmaceutical Sciences, 1994